

CIN: L24222TN1992PLC022994

June 19, 2014

**The Manager
Listing Department
National Stock Exchange of India Ltd
Exchange Plaza, 5th Floor, Plot No: C/1
G - Block, Bandra - Kurla Complex
Bandra (East)
Mumbai – 400 051**

Dear Sir/Madam,

In accordance with the requirements of the Listing Agreement, we would like to inform that Orchid has received the approval from the US FDA for the Abbreviated New Drug Application (ANDA) for Eszopiclone Tablets.

A copy of the press release issued by the Company is enclosed for your reference and records.

Thanking you,

Yours faithfully,



**L Chandrasekar
Executive V P – Finance & Secretary**

Encl.: a/a

Media Release

Chennai, India – June 19, 2014

Orchid receives US FDA approval for Eszopiclone Tablets ANDA

The Chennai-based pharma major, Orchid Chemicals & Pharmaceuticals Ltd (Orchid) today announced that it has received approval from the US FDA for its ANDA (Abbreviated New Drug Application) for Eszopiclone Tablets, 1 mg, 2 mg, and 3 mg strengths.

Safe Harbour

"This media release includes forward looking statements and indications, which are based on current expectations and forecasts about future events. Such statements and indications involve known and unknown risks, uncertainties and other factors and may cause actual results to materially differ. Such factors include, but are not limited to, changes in local and global economic conditions, Orchid's ability to successfully implement strategies, the market acceptance and demand of Orchid's products and services, Orchid's growth rates, expansion, technological change and Orchid's exposure to market risks. By their nature, these statements and indications are only estimates and actual results could differ from these in the future."

